Evidence map›Paper›PMID 40138428›Full record

ArticleScience advances2025

Systematic high-throughput evaluation reveals FrCas9's superior specificity and efficiency for therapeutic genome editing.

Rui Tian, Xun Tian, Meiying Yang, Yuping Song, Tingting Zhao, Chaoyue Zhong, Wei Zhu, Ping Zhou, Zhiqiang Han, Zheng Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rui TianGenerulor Company Bio-X Lab, Zhuhai 519000, China.
Xun TianDepartment of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, Hubei, China.ORCID 0000-0002-4602-7589
Meiying YangDepartment of Gynecology, Guilin People's Hospital, Guilin 541000, China.
Yuping SongDepartment of Dermatology, Wuhan Donghu Hospital, Wuhan 430074, Hubei, China.ORCID 0009-0003-0335-914X
Tingting ZhaoGenerulor Company Bio-X Lab, Zhuhai 519000, China.
Chaoyue ZhongGenerulor Company Bio-X Lab, Zhuhai 519000, China.
Wei ZhuGenerulor Company Bio-X Lab, Zhuhai 519000, China.ORCID 0000-0003-1459-6733
Ping ZhouDepartment of Obstetrics and Gynecology, Dongguan Maternal and Child Health Care Hospital, Dongguan 523000, China.
Zhiqiang HanDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.ORCID 0000-0001-8353-3491
Zheng HuDepartment of Gynecologic Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.ORCID 0000-0001-9306-9442

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-Cas9 systems have revolutionized genome editing, but the off-target effects of Cas9 limit its use in clinical applications. Here, we systematically evaluate FrCas9, a variant from

Indexed as

CRISPR-Associated Protein 9CRISPR-Cas SystemsGene EditingGenetic TherapyAnimalsHigh-Throughput Nucleotide SequencingHumansRNA, Guide, CRISPR-Cas SystemsCRISPR-Associated Protein 9RNA, Guide, CRISPR-Cas Systems

Identifiers

PMID40138428
PMCPMC11939069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.